Survival impact of adjuvant concurrent chemoradiotherapy after radical hysterectomy in FIGO stage IIIC1 cervical adenocarcinoma

We evaluated the survival effect of adjuvant concurrent chemoradiotherapy after radical hysterectomy in patients with clinical pelvic node-positive cervical adenocarcinoma. Patients adenocarcinoma diagnosed between 2000 and 2016 at our institution were identified. Survival was compared who underwent alone those received as an treatment. analysis using log-rank test Cox proportional hazards model performed. identified 80 for adenocarcinoma; these, four pathological node-negative excluded. Of 76 patients, 27 49 followed by chemoradiotherapy. With a median follow-up 53 months, 5-year overall rate 51.0% versus 53.0% additional (log-rank p = 0.455). The addition did not significantly improve among More appropriate treatment strategies are needed to outcomes these patients.